Stelexis is a cancer therapeutics company, utilizing its proprietary platform to selectively target pre-cancerous stem cells to discover and develop transformative therapies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/08/19 | $43,000,000 | Series A |
Deerfield Partners | undisclosed |
